BACKGROUND Amino acid PET using O-(2-[18F]fluoroethyl)-L-tyrosine (FET) provides important additional information on the extent of viable tumor tissue of glioblastoma compared with MRI. Especially after radiochemotherapy, progression of contrast enhancement in MRI can be equivocal and may represent either true tumor progression or treatment-related changes. We present the first case comparing post-mortem whole-brain histopathology in progressive glioblastoma with dynamic in vivo FET PET and MRI.METHODSA 61-year-old glioblastoma patient underwent initially partial resection and died eleven weeks after completion of chemoradiation with concurrent temozolomide. Three days before the patient died, a follow-up FET PET and MRI scan indicated loca...
The aim of this study was to assess the clinical value of O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-...
Early detection of treatment response in glioma patients after radiochemotherapy (RCX) is uncertain ...
In glioma patients, differentiation between tumor progression (TP) and treatment-related changes (TR...
ObjectiveAmino acid positron emission tomography (PET) using O-(2-[18F]fluoroethyl)-L-tyrosine (FET)...
BackgroundA complete glioma resection is known to prolong survival. Contrast enhancement (CE) in MRI...
PurposeWe present our first clinical experience with O-(2-18F-fluoroethyl)-l-tyrosine (FET) PET in p...
The PET tracer O-(2-[18F]Fluoroethyl)-l-tyrosine (FET) has been shown to be valuable for different r...
AbstractBACKGROUNDIn patients with glioblastoma, the tissue showing contrast enhancement (CE) in MRI...
Gliomas are the most frequent primary tumors of the brain. They can be divided into grade II-IV astr...
Abstract Accurate determination of the extent and grade of adult-type diffuse gliomas is critical to...
In glioma patients, differentiation between tumor progression (TP) and treatment-related changes (TR...
PurposeThe follow-up of glioblastoma patients after radiochemotherapy with conventional MRI can be d...
Gliomas are the most frequent primary tumors of the brain. They can be divided into grade II-IV astr...
MRI is commonly used to determine the location and extent of cerebral gliomas. We investigated wheth...
The assessment of treatment response in glioblastoma is difficult with MRI because reactive blood-br...
The aim of this study was to assess the clinical value of O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-...
Early detection of treatment response in glioma patients after radiochemotherapy (RCX) is uncertain ...
In glioma patients, differentiation between tumor progression (TP) and treatment-related changes (TR...
ObjectiveAmino acid positron emission tomography (PET) using O-(2-[18F]fluoroethyl)-L-tyrosine (FET)...
BackgroundA complete glioma resection is known to prolong survival. Contrast enhancement (CE) in MRI...
PurposeWe present our first clinical experience with O-(2-18F-fluoroethyl)-l-tyrosine (FET) PET in p...
The PET tracer O-(2-[18F]Fluoroethyl)-l-tyrosine (FET) has been shown to be valuable for different r...
AbstractBACKGROUNDIn patients with glioblastoma, the tissue showing contrast enhancement (CE) in MRI...
Gliomas are the most frequent primary tumors of the brain. They can be divided into grade II-IV astr...
Abstract Accurate determination of the extent and grade of adult-type diffuse gliomas is critical to...
In glioma patients, differentiation between tumor progression (TP) and treatment-related changes (TR...
PurposeThe follow-up of glioblastoma patients after radiochemotherapy with conventional MRI can be d...
Gliomas are the most frequent primary tumors of the brain. They can be divided into grade II-IV astr...
MRI is commonly used to determine the location and extent of cerebral gliomas. We investigated wheth...
The assessment of treatment response in glioblastoma is difficult with MRI because reactive blood-br...
The aim of this study was to assess the clinical value of O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-...
Early detection of treatment response in glioma patients after radiochemotherapy (RCX) is uncertain ...
In glioma patients, differentiation between tumor progression (TP) and treatment-related changes (TR...